Ma

ZYMERGEN INVESTIGATION: Block & Leviton Investigates Zymergen For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, August 4, 2021
Leviton

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Zymergen, Inc. (NASDAQ: ZY) for potential securities law violations.

Key Points: 
  • BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Zymergen, Inc. (NASDAQ: ZY) for potential securities law violations.
  • Investors who have lost money in their Zymergen investment should contact the firm to learn more about how they might recover those losses.
  • Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
  • If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website , by email at [email protected] , or by phone at (617) 398-5600.

Japan’s Z Holdings Enhances IP Management with Anaqua AQX Platform

Retrieved on: 
Wednesday, August 4, 2021

When upgrading its previous IP management system, Z Holdings chose Anaquas AQX platform as the group was seeking a global solution that would streamline its entire IP management lifecycle; improve financial management and budgeting; and enhance communications within group companies in order to better exploit licensing opportunities.

Key Points: 
  • When upgrading its previous IP management system, Z Holdings chose Anaquas AQX platform as the group was seeking a global solution that would streamline its entire IP management lifecycle; improve financial management and budgeting; and enhance communications within group companies in order to better exploit licensing opportunities.
  • The AQX platforms fully integrated software and services will support Z Holdings in trademark and patent management processes globally, providing real-time IP data analytics and forecasting capabilities, and helping identify licensing and other monetization opportunities.
  • Anaquas AQX platform combines best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations.
  • Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs.

Avid Technology Announces Second Quarter 2021 Results

Retrieved on: 
Tuesday, August 3, 2021

BURLINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Avid® (NASDAQ: AVID), a leading technology provider that powers the media and entertainment industry, today announced its financial results for the second quarter ended June 30, 2021, provided guidance for the third quarter of 2021, raised full-year guidance for Free Cash Flow, and reaffirmed all other full-year 2021 guidance.

Key Points: 

AMSC Announces $21 Million of New Energy Power System Orders

Retrieved on: 
Tuesday, August 3, 2021
AMSC

AYER, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- AMSC (NASDAQ: AMSC), aleading system provider of megawatt-scale power resiliency solutions thatorchestratethe rhythm and harmony of power on the grid and protect and expand the capability of our Navys fleet, today announced $21 million of new energy power systems orders.

Key Points: 
  • AYER, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- AMSC (NASDAQ: AMSC), aleading system provider of megawatt-scale power resiliency solutions thatorchestratethe rhythm and harmony of power on the grid and protect and expand the capability of our Navys fleet, today announced $21 million of new energy power systems orders.
  • Leveraging the strong combination of our new energy power systems solutions, bookings are off to a strong start for the year.
  • AMSCs new energy power systems solutions include D-VAR and VVO offerings as well as the recently acquired NEPSI and Neeltran businesses.
  • AMSC generates the ideas, technologies and solutions that meet the worlds demand for smarter, cleaner better energy.

Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, August 3, 2021
Financial markets, Finance, Money, Encodings, Stock market, Ticker symbol, NASDAQ, U.S. Securities and Exchange Commission

Immuneerings Class A common stock began trading on the Nasdaq Global Market under the ticker symbol IMRX on July 30, 2021.

Key Points: 
  • Immuneerings Class A common stock began trading on the Nasdaq Global Market under the ticker symbol IMRX on July 30, 2021.
  • A registration statement relating to the securities being sold in the offering was declared effective by the U.S. Securities and Exchange Commission on July 29, 2021.
  • Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses.
  • Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Economy of New York City, NASDAQ, Finance, Financial markets, Investment

In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employees entry into employment with the Company.

Key Points: 
  • In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employees entry into employment with the Company.
  • In connection with the commencement of employment, the employees received stock options on August 2, 2021, to purchase an aggregate 28,000 shares of Allena common stock.
  • The stock options were granted pursuant to Allenas 2021 Inducement Plan and have an exercise price of $0.95 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
  • Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Kidney diseases, Organs anatomy), Clinical medicine, Hyperoxaluria, Hyperuricemia, Kidney stone disease, Oxalate, Kidney, Uric acid, Chronic kidney disease

Management will also be available for 1x1 meetings onTuesday, August 10th Wednesday, August 11th, 2021.

Key Points: 
  • Management will also be available for 1x1 meetings onTuesday, August 10th Wednesday, August 11th, 2021.
  • Allena Pharmaceuticals, Inc.is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.
  • Allenas lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
  • Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program planned for the second half of 2021.

Rapid Micro Biosystems Announces Appointment of Melinda Litherland to Board of Directors

Retrieved on: 
Tuesday, August 3, 2021
Academic journals, Life, Publications

LOWELL, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (Rapid Micro), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Melinda Litherland to its board of directors.

Key Points: 
  • LOWELL, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (Rapid Micro), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Melinda Litherland to its board of directors.
  • She also serves on the board of directors at Bio-Rad Laboratories, Inc., chairing the audit committee.
  • We are thrilled to welcome a board member with Melindas extensive financial and life sciences background to Rapid Micro Biosystems, said President and CEO Robert Spignesi.
  • I am excited to join the board at Rapid Micro Biosystems at an energizing time in the company's growth, Litherland said.